Safe and reproducible delivery of gene therapy vector into the subretinal space is essential for successful targeting of the retinal pigment epithelium (RPE) and photoreceptors. The success of ...

The pharma is dipping its toe in the water through the deal to access a vector that 4DMT has used for four different product candidates. The furthest along is 4D-150, which is in phase 1/2 trials ...

Dyno Therapeutics Launches Dyno eCap 1™ Vector, a Field-Leading AAV Capsid for Eye Gene Therapies - 80x improvement vs. AAV2 in delivery to the retina seen across multiple non-human primate (NHP ...